Will Roche and Ionis submit an NDA for sefaxersen to the FDA by 30 September 2026?
Posted 2026-09-23 — 7 days before the deadline, stated before the outcome.
Roche and Ionis are pharmaceutical companies developing sefaxersen, a therapeutic agent. The New Drug Application is the formal regulatory submission required by the US Food and Drug Administration to approve a new medication.
The claim
Roche and Ionis will submit a New Drug Application (NDA) for sefaxersen to the US FDA by 30 September 2026.
Reasoning trace
- Successful interim results meeting primary endpoint allow for immediate regulatory dialogue and filing.
- Competitive pressure from Novartis to secure market position in IgA nephropathy accelerates development timeline.
Evidence so far
0 confirming · 0 denying signals · 2 verified · 1 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 1 time since mint (last on 2026-09-23) — 80% at mint → 80% today.
What to watch
- leading indicator Roche or Ionis issues a public press release announcing the submission of the New Drug Application for sefaxersen to the US FDA
- leading indicator Roche and Ionis announce a joint regulatory filing or confirm the NDA submission date in a public investor update or earnings call transcript.
- milestone The US FDA's Drugs@FDA database lists a new application for sefaxersen with a receipt date on or before 30 September 2026.
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.